fda on compounded semaglutide ends shortage, closing the door Wegovy, Ozempic FDA crackdown on off-brand Ozempic

The FDA has reported adverse events, including hospitalizations, linked to overdoses and dosing errors with compounded semaglutide, often from patients measuring incorrectly or clinicians miscalculating

Glucagon-like peptide-1 agonists, or GLP-1s, are prescription drugs that were first authorized to treat type 2 diabetes

See details and protocol in this application note: Measuring Insulin Release Following GLP-1 Receptor Agonist Treatment Using the Lumit Insulin Immunoassay

This is my understanding and Im hoping you can add clarity or potentially make a post addressing these concerns

By targeting appetite and metabolic regulation, the treatment helps many patients reduce food intake and achieve meaningful weight loss